Valuation: Roche Holding AG

Capitalization 252B 324B 275B 238B 443B 30,570B 447B 2,985B 1,164B 14,684B 1,214B 1,189B 50,696B P/E ratio 2026 *
16.7x
P/E ratio 2027 * 15.5x
Enterprise value 262B 337B 287B 248B 462B 31,851B 466B 3,111B 1,213B 15,299B 1,265B 1,239B 52,820B EV / Sales 2026 *
4.18x
EV / Sales 2027 * 3.89x
Free-Float
88.75%
Yield 2026 *
3.18%
Yield 2027 * 3.26%
1 day-0.94%
1 week-0.97%
Current month-0.97%
1 month-0.44%
3 months-10.88%
6 months+17.47%
Current year-3.93%
1 week 313.8
Extreme 313.8
325.8
1 month 312
Extreme 312
326.7
Current year 291
Extreme 291
374.9
1 year 243.9
Extreme 243.9
374.9
3 years 212.9
Extreme 212.9
374.9
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 15/03/2023
Director of Finance/CFO 59 06/06/2011
Chief Operating Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 68 01/01/1996
Chairman 59 15/03/2023
Director/Board Member 73 03/03/2015
Change 5d. change 1-year change 3-years change Capi.($)
-0.94%-0.97%+22.40%+11.18% 324B
-2.72%-1.54%+29.12%+121.40% 846B
-0.53%-2.58%+43.51%+37.42% 533B
-0.57%-2.44%+9.18%+37.27% 356B
+0.23%-1.24%+30.31%+12.00% 282B
+0.05%-2.19%+24.69%+21.29% 278B
-0.82%-0.70%+46.61%-5.15% 275B
-1.76%+4.42%-34.66%-49.15% 203B
+0.79%+0.57%+24.76%+41.49% 179B
-2.04%-0.24%+35.52%+66.66% 163B
Average -0.83%-0.69%+23.14%+29.44% 343.84B
Weighted average by Cap. -1.10%-1.22%+26.11%+45.29%

Financials

2026 *2027 *
Net sales 62.74B 80.69B 68.55B 59.22B 110B 7,621B 111B 744B 290B 3,660B 303B 296B 12,637B 65.33B 84.03B 71.39B 61.66B 115B 7,936B 116B 775B 302B 3,812B 315B 309B 13,160B
Net income 14.78B 19.01B 16.15B 13.95B 26.02B 1,795B 26.25B 175B 68.35B 862B 71.32B 69.82B 2,977B 15.8B 20.32B 17.27B 14.91B 27.82B 1,919B 28.07B 187B 73.07B 922B 76.24B 74.64B 3,183B
Net Debt 10.54B 13.56B 11.52B 9.95B 18.56B 1,281B 18.73B 125B 48.76B 615B 50.88B 49.81B 2,124B 2.71B 3.49B 2.97B 2.56B 4.78B 330B 4.82B 32.19B 12.55B 158B 13.1B 12.82B 547B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
08/05/26 315.30 CHF -0.94% 590,249
07/05/26 318.30 CHF -1.12% 690,846
06/05/26 321.90 CHF +1.07% 806,860
05/05/26 318.50 CHF +0.63% 509,079
04/05/26 316.50 CHF -0.60% 497,068
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
315.30CHF
Average target price
360.76CHF
Spread / Average Target
+14.42%

Quarterly revenue - Rate of surprise